NewswireToday - /newswire/ -
Rehovot, Israel, 2012/02/08 - Foamix Ltd, a clinical-stage specialty pharmaceutical company, announced that the company has been granted a patent from Indian Patent Office # IN 249626, entitled “Foam Carrier Containing Amphiphilic Copolymeric Gelling Agent” - Foamix.co.il.
Foamix Ltd, a clinical-stage specialty pharmaceutical company, that is developing proprietary dermatological and gynecologic topical foam products, today announced that the company has been granted a patent from Indian Patent Office # IN 249626, entitled “Foam Carrier Containing Amphiphilic Copolymeric Gelling Agent.” The patent concerns a platform of versatile emollient foam formulations, which are suitable for carrying dermatological drugs, such as antibiotics, antifungals, corticosteroids, anti-inflammatory, anti-acne and anti-rosacea drugs.
This is Foamix’s third granted patent in India. Foamix already holds granted patents for its foam formulations in the United States, Canada, Australia, Mexico, New Zealand, South Africa and Israel.
"Our investors elected early on to develop a first class intellectual property portfolio with the foresight that there will be a demand for products based on our foam technology," remarks Dr. Dov Tamarkin, CEO of Foamix. "We are pleased that patent offices around the world recognize Foamix's innovation in the field of topical foams."
Foamix Ltd (foamix.co.il) is a clinical-stage, privately held specialty pharmaceutical company, focused on the development of proprietary topical foams and OilGel™ products for dermatology, gynecology, wounds and burn applications, as well as ophthalmic disorders. Foamix collaborates with leading pharmaceutical companies in the creation of advanced products with improved convenience, higher compliance and better efficacy, which are backed by an extensive patent portfolio.
The Company’s development capabilities range from initial development of the formulations to scale-up, GMP manufacturing, preclinical and clinical studies.
Foamix has a strong in-house pipeline. The Company’s lead product, Topical Minocycline, is currently in Phase II clinical studies.
To date, Foamix has 9 issued patents in the United States, covering its foam and OilGel™ technology platforms. Additionally, the company has more than 140 patents and patent applications worldwide, of which about 60 applications are filed in the U.S.